Bicara Therapeutics Inc. 8K

Bicara Therapeutics reported Q2 2026 results, detailed progress on its pivotal ficerafusp alfa programs, and announced a planned CEO transition and broader executive leadership reshuffle as it prepares for potential commercialization.

On August 11, 2026, Bicara Therapeutics Inc. reported its second quarter 2026 financial results and provided a business update that included several significant planned leadership transitions and clinical development milestones. The company announced that President & COO Ryan Cohlhepp will succeed current CEO Claire Mazumdar as President & CEO effective January 1, 2027, with Dr. Mazumdar moving to the role of Vice Chair of the Board and Strategic Advisor to support a smooth transition as the company prepares for potential commercialization of its lead asset, ficerafusp alfa, in first-line HPV‑negative head and neck squamous cell carcinoma. Concurrently, Chief Development Officer Tanya Green will be promoted to COO on January 1, 2027, and Chief Corporate Affairs Officer Jenna Cohen will become Chief Business Officer on that date, while Jenn Larson has been appointed CFO effective August 12, 2026, replacing Ivan Hyep, and Greg Shiferman has been appointed Chief Legal Officer effective August 31, 2026. Operationally, Bicara reported continued enrollment progress in its pivotal Phase 3 FORTIFI‑HN01 trial in 1L R/M HPV‑negative HNSCC, initiation of the FORTIFI‑FLEX alternate dosing study of ficerafusp alfa plus pembrolizumab, and presentation of three‑year Phase 1/1b data showing improved overall survival versus standard of care. Financially, as of June 30, 2026, the company held $497.3 million in cash, cash equivalents, and marketable securities, expects its cash runway to extend into the first half of 2029, and recorded a second quarter 2026 net loss of $55.4 million driven primarily by increased R&D and G&A expenses related to pivotal trial activities and commercialization readiness.

Filing Facts

CIK

2023658

Ticker

BCAX

Form

8K

Source Type

fda

Accession

0001628280-26-055500

Alert Tier

7